Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Vascular Calcification

Therapeutic Apheresis and Dialysis

Volumn 15, Issue 2, 2011, Pages 140-146

  Chasseraud, Maud ^a   Liabeuf, Sophie ^a,b   Mozar, Anaïs ^a   Mentaveri, Romuald ^a   Brazier, Michel ^a,b   Massy, Ziad A ^a,b   Kamel, Saïd ^a,b  

^a UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^b AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

Chronic kidney disease; Osteoprotegerin; Tumor necrosis factor related apoptosis inducing ligand; Uremia; Vascular calcification

Indexed keywords

APOLIPOPROTEIN E; MESSENGER RNA; OSTEOPROTEGERIN; PHOSPHATE; RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; AORTA VALVE; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL CALCIFICATION; CD3+ T LYMPHOCYTE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; MOUSE; MULTIDETECTOR COMPUTED TOMOGRAPHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SCORING SYSTEM; SMOOTH MUSCLE FIBER; UREMIA; VASCULAR SMOOTH MUSCLE; WILD TYPE;

AGED; ANIMALS; APOLIPOPROTEINS E; CALCINOSIS; CELLS, CULTURED; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; KIDNEY DISEASES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MIDDLE AGED; MUSCLE, SMOOTH, VASCULAR; OSTEOPROTEGERIN; PLAQUE, ATHEROSCLEROTIC; RENAL DIALYSIS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; UREMIA;

EID: 79953050192     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2010.00886.x     Document Type: Article

References (24)

1. Massy ZA, Mentaverri R, Mozar A, Brazier M, Kamel S. The pathophysiology of vascular calcification: are osteoclast-like cells the missing link? Diabetes Metab 2008;34(Suppl 1):S16-20.
2. Morena M, Terrier N, Jaussent I etal. Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J Am Soc Nephrol 2006;17:262-70.
3. Ziegler S, Kudlacek S, Luger A, Minar E. Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. Atherosclerosis 2005;182:175-80.
4. Morena M, Dupuy AM, Jaussent I etal. A cut-off value of plasma osteoprotegerin level may predict the presence of coronary artery calcifications in chronic kidney disease patients. Nephrol Dial Transplant 2009;24:3389-97.
5. Secchiero P, Candido R, Corallini F etal. Systemic tumor necrosis factor-related apoptosis-inducing ligand delivery shows antiatherosclerotic activity in apolipoprotein E-null diabetic mice. Circulation 2006;114:1522-30.
6. Zauli G, Pandolfi A, Gonelli A etal. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially upregulates nitric oxide and prostanoid production in primary human endothelial cells. Circ Res 2003;92:732-40.
7. Corallini F, Rimondi E, Secchiero P. TRAIL and osteoprotegerin: a role in endothelial physiopathology? Front Biosci 2008;13:135-47.
8. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996;271:12687-90.
9. Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 1997;7:813-20.
10. Martin-Ventura JL, Munoz-Garcia B, Egido J, Blanco-Colio LM. Trail and vascular injury. Front Biosci 2007;12:3656-67.
11. Michowitz Y, Goldstein E, Roth A etal. The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis. J Am Coll Cardiol 2005;45:1018-24.
12. Schoppet M, Sattler AM, Schaefer JR, Hofbauer LC. Osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) levels in atherosclerosis. Atherosclerosis 2006;184:446-7.
13. Sato K, Niessner A, Kopecky SL, Frye RL, Goronzy JJ, Weyand CM. TRAIL-expressing T cells induce apoptosis of vascular smooth muscle cells in the atherosclerotic plaque. J Exp Med 2006;203:239-50.
14. Liabeuf S, Barreto DV, Barreto FC etal. The circulating soluble TRAIL is a negative marker for inflammation inversely associated with the mortality risk in chronic kidney disease patients. Nephrol Dial Transplant 2010;25:2596-602.
15. Massy ZA, Ivanovski O, Nguyen-Khoa T etal. Uremia accelerates both atherosclerosis and arterial calcification in apolipoprotein E knockout mice. J Am Soc Nephrol 2005;16:109-16.
16. Temmar M, Liabeuf S, Renard C etal. Pulse wave velocity and vascular calcification at different stages of chronic kidney disease. J Hypertens 2010;28:163-9.
17. Barreto DV, Barreto FC, Liabeuf S etal. Vitamin D affects survival independently of vascular calcification in chronic kidney disease. Clin J Am Soc Nephrol 2009;4:1128-35.
18. Kauppila LI, Polak JF, Cupples LA, Hannan MT, Kiel DP, Wilson PW. New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study. Atherosclerosis 1997;132:245-50.
19. Proudfoot D, Skepper JN, Hegyi L, Bennett MR, Shanahan CM, Weissberg PL. Apoptosis regulates human vascular calcification in vitro: evidence for initiation of vascular calcification by apoptotic bodies. Circ Res 2000;87:1055-62.
20. Schoppet M, Al-Fakhri N, Franke FE etal. Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Monckeberg's sclerosis and atherosclerosis. J Clin Endocrinol Metab 2004;89:4104-12.
21. Kiechl S, Schett G, Wenning G etal. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004;109:2175-80.
22. Barreto DV, Barreto FC, Carvalho AB etal. Coronary calcification in hemodialysis patients: the contribution of traditional and uremia-related risk factors. Kidney Int 2005;67:1576-82.
23. Jono S, Ikari Y, Shioi A etal. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002;106:1192-4.
24. Gonnelli S, Montagnani A, Caffarelli C etal. Osteoprotegerin (OPG) and receptor activator of NF-kB ligand (RANK-L) serum levels in patients on chronic hemodialysis. J Endocrinol Invest 2005;28:534-9.